Home | Business News | Browse by Publication | B | Business Wire

Oscient Pharmaceuticals to Present Clinical Data on FACTIVE(R) Tablets at Chest 2005; Data Presentations Address Utility of FACTIVE in High-Risk Patients and against Resistant Infections.

Article Excerpt
WALTHAM, Mass. -- - Four poster presentations highlighting data from Oscient Pharmaceuticals' (Nasdaq: OSCI) FDA-approved fluoroquinolone antibiotic, FACTIVE(R) (gemifloxacin mesylate) tablets, are being presented at CHEST 2005, the Annual Meeting of the American College of Chest Physicians (ACCP). Included in the program are data exploring the clinical activity of FACTIVE in treating acute bacterial exacerbations of chronic bronchitis (AECB), community-acquired pneumonia (CAP) in patients with risk factors and co-morbidities and respiratory tract infections caused by resistant bacteria.

"The data in these posters reinforce the use of FACTIVE, the most potent fluoroquinolone in vitro, as a first-line agent for CAP and AECB patients with co-morbidities," stated Steven M. Rauscher, President and Chief Executive Officer. "Our data also support the recommendations made in recent AECB and CAP treatment guidelines that these are the patients for whom fluoroquinolone therapy is the most appropriate choice."

Presentation Schedule Wednesday, November 2, 2005, 12:30 pm - 2:00 pm: Session ID 1799 -- Poster #578 - Patient Risk Factors in Community-Acquired Pneumonia Infections Outcome Following Treatment with Gemifloxacin -- Meta-analysis of five Phase III trials examined clinical outcomes in patients being treated for community-acquired pneumonia with diabetes,...